Ambrilia Biopharma Inc.

Ambrilia Biopharma Inc.

June 13, 2007 08:01 ET

Ambrilia Presents Data on its Novel HIV Integrase Inhibitors at the XVI International HIV Drug Resistance Workshop

MONTREAL, QUEBEC--(Marketwire - June 13, 2007) - Ambrilia Biopharma Inc. (TSX:AMB), a biopharmaceutical company developing small molecules and peptides to treat infectious diseases and cancer, presented preclinical data on its novel series of HIV integrase inhibitors, showing their potential distinct mechanism of action, which may lead to a different resistance profile from known integrase inhibitors currently in clinical development. The abstract entitled "Novel Small Molecule Inhibitors of HIV-1 Integrase" was presented during a poster session at the XVI International HIV Drug Resistance Workshop in Barbados (June 12-16).

"Integrase inhibitors emerge as one of the most promising new classes of drugs for the treatment of HIV/AIDS. These data suggesting that Ambrilia has potentially a new category of HIV integrase inhibitors underway are encouraging. Thus, development of these compounds is one of our priorities for the coming months and into next year", said Dr. Bonabes de Rouge, Senior Executive Vice-President and Chief Scientific Officer of Ambrilia. "As well, we are pleased to have collaborated with Merck on the PPL-100 abstract, an oral presentation at the same conference, which presents new data on the structural basis for PPL-100's favorable resistance profile", he concluded.

Ambrilia co-authored, along with Dr. Mark Wainberg of McGill University, Merck's abstract entitled "Structural Basis for the Resistance Profile of the HIV-1 Protease Inhibitor PL-100", presented by Dr. Joseph Vacca, Executive Director, Medicinal Chemistry (Virology), Merck Research Labs, USA, on June 13th (oral session: "Resistance to New Antiretroviral Agents"). In the presentation, the mutational profile of PL-100 was deduced from a model and subsequent X-ray crystal structure. This information can aid in the understanding of the resistance profile of PPL-100 in protease inhibitor-experienced HIV patients.


The poster presents a novel series of pyrazolopyridine integrase inhibitors developed by Ambrilia. These compounds demonstrated potent inhibition of integrase strand transfer activity but did not exhibit significant inhibition of integrase 3'-processing activity. Some of the compounds showed good activity against HIV-1 viruses in cellular assays without cytotoxicity. Preliminary inhibitor cross-competition studies showed that the pyrazolopyridine compounds did not compete kinetically with known competitive strand transfer inhibitors such as diketo acid compounds, suggesting a different mechanism of action or a different binding site. The findings suggest that these novel pyrazolopyridine integrase inhibitors have a potentially distinct mechanism of strand transfer inhibition, which may lead to a different resistance profile from known strand transfer inhibitors currently in clinical development.

The poster is available on Ambrilia's web site at:

Ambrilia's forward-looking statements

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the Company's filings. We refer you to the Risk Factors section of the Company's Management's Discussion & Analysis of Financial Condition and Results of Operations which contain a more exhaustive analysis of the risks and uncertainties that are generally connected to the business of the Company. Such statements are also based on various assumptions, including the successful and timely completion of clinical studies on Ambrilia's products demonstrating efficacy and safety for human use, their successful commercialization within the forecasted timelines and the attainment of the forecasted milestone payments and other revenues. While Ambrilia anticipates that subsequent events and developments may cause Ambrilia's views to change, Ambrilia specifically disclaims any obligation to update these forward looking statements.


The International HIV Drug Resistance Workshop has gained a reputation over the last 16 years as being the premier meeting on HIV drug resistance. Leading laboratory and clinical scientists present their latest research at this Workshop, which often results in innovative approaches to antiretroviral therapy. The Workshop is renowned for the quality of the data presented and the depth of the scientific interaction and debate.


Ambrilia Biopharma Inc. (TSX:AMB) is a biopharmaceutical company developing novel small molecules and peptides to treat infectious diseases and cancer. Ambrilia's product portfolio includes promising anti-HIV treatments (PPL-100 and an HIV Integrase Inhibitor Program), two new formulations of existing drugs developed with a patented technology (Octreotide and Goserelin), an anti-cancer therapeutic peptide (PCK3145), a tumor and tumor-vasculature targeting (TVT) technology platform, as well as other anti-virals and immunomodulators. Exclusive worldwide rights to PPL-100 and its related compounds have been granted to Merck & Co., Inc. in return for a $US17 million upfront payment, potential milestones that could reach $US212 million, and royalties. Ambrilia's head office, research and development and manufacturing facilities are located in Montreal with a regional office in France.


Contact Information